Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.

http://www.wikidata.org/entity/Q35212727

about

Targeted drugs in small-cell lung cancer Cellular and molecular biology of small cell lung cancer: an overview Novel therapies in small cell lung cancer Regulation of Bim in Health and Disease Origins, genetic landscape, and emerging therapies of small cell lung cancer The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient.BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies.BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma.To Prime, or Not to Prime: That Is the Question.Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope.Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer.Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM.Venetoclax is effective in small cell lung cancers with high BCL-2 expression.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer.Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.Pathways and mechanisms of venetoclax resistance.Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity BH3 mimetics induce apoptosis independent of DRP-1 in melanoma BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer

P2860

Q26767017-FF05033D-6494-4805-9EFC-4C12446C76A5 Q26767029-45DF713A-DA49-414F-ADB6-6F13502159C9 Q26775390-2D986271-C6DC-47F7-AD47-1D0F02E04686 Q26781203-67EF148A-C87E-41EB-9179-305209A08B7E Q26798218-6B0A3C5A-4E23-4398-82D6-9AB81493BB16 Q27010154-300FD79D-7918-4001-896B-8AF53FFFB090 Q28077504-13C0AD86-CE14-437A-A268-9BCEC07BCB40 Q28118450-D5B7A297-32C9-42F9-92D7-34B7A950A712 Q30276619-5E95A746-A89D-47A1-B491-85CE28FBCAE3 Q33851111-FDBD93D1-43EB-49B5-8FE2-35AE862E4F6B Q36275612-5284D991-CD7B-42D4-BCE7-230B770F3655 Q36284637-EDE962C0-0922-404E-B325-9E1AEF8F7E8E Q36350128-E8377E50-3A10-47AD-A5C8-54EC24AE0B60 Q36811784-6FB720EA-CEE6-48BB-88BB-B545C3D3FEA1 Q37164249-3FFEA039-DE68-4797-BB2D-6F9BC867205D Q37317126-9AC55B0C-4B39-4F66-9D33-4D49A054FFDD Q38677019-D132CB06-E217-4617-82D7-BE9E847CB345 Q38798849-1B6909AE-BC24-4E78-8053-C50D35D14823 Q39393217-B868CA56-F24F-4178-A862-16E88DAE6A1C Q41077849-9A60AE63-454B-428D-AA5B-2DB2CA754C84 Q42242957-D4690F92-6826-4C14-AAAC-41BDE23D61BF Q42283077-225CE0F7-81BE-4B00-B83B-EC1626448A18 Q42503679-B6297EA7-7491-4A1B-B2D6-11FE4ACE5D63 Q44268034-2F0648DB-B89D-4685-80F9-CCE527853163 Q45070526-553D0B89-6FBC-4038-8BF5-AB38B3B7822F Q45072361-93D25DC4-1382-47C3-87A7-52B9E857C261 Q46370948-CB96486F-0DD0-4439-B681-E9CBC00D5D8E Q48158175-2FC35761-9070-4C79-82FB-67D5C34DF437 Q49988930-E5D30104-9C12-4482-A6BE-10B3DF64A2C0 Q50145710-39A92C76-5820-4AC0-9413-C0714363C5B8 Q51160342-2C0F7DA3-8C9D-4177-9755-0D02AABBD331 Q54985966-140BA230-477D-456B-9F82-A4458E5D3E79 Q55263786-659B463F-162D-4396-B132-1271BE86B237 Q56811078-9219C07F-62F7-419C-A978-154D1B51AA35 Q58603251-21E1A9FF-0EAE-468A-8257-2860DE69FE46 Q58695490-2F18B3AE-0E86-401C-863F-5EC8D40324E1 Q58763373-2DE7AB70-8570-475C-82BE-75743491CA6B Q58779838-2249B412-9479-40BF-BF1A-E0F20169C0EE

P2860

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.

http://www.wikidata.org/entity/Q35212727

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Assessment of ABT-263 activity ...... py for small-cell lung cancer.

@ast

Assessment of ABT-263 activity ...... py for small-cell lung cancer.

@en

type

label

Assessment of ABT-263 activity ...... py for small-cell lung cancer.

@ast

Assessment of ABT-263 activity ...... py for small-cell lung cancer.

@en

prefLabel

Assessment of ABT-263 activity ...... py for small-cell lung cancer.

@ast

Assessment of ABT-263 activity ...... py for small-cell lung cancer.

@en

P1433

Q35212727-60AC9CDD-7104-47AE-9CFC-86FB0A90C53A

P1476

Q35212727-375A848F-207E-4EEF-95BE-7F2C0FE270E0

P2093

Q35212727-06D3C587-AEBD-40EF-8C39-CADD92D4487F

Q35212727-25A69D83-A4FC-47B6-BB4D-56AE7229C450

Q35212727-3F6A2590-B511-46FB-9E6A-AB7956A53094

Q35212727-3FFF1279-805F-493B-9A5F-A11291FD7A22

Q35212727-40676390-F8D2-43C0-A558-0B7B00FA84A0

Q35212727-46E24750-EEDF-4A65-B87E-E3BEEC13F4CE

Q35212727-48D51388-3299-4EE3-9324-BEA386A74890

Q35212727-4A5E800D-2701-4215-A06D-D0FE7A1A9BB3

Q35212727-5E0E0DFB-0716-4F79-A73D-1BBDF337D679

Q35212727-6483D84F-C5AE-4B66-8F04-4E7EF17B6362

P2860

Q35212727-0E7A07B6-B19C-4FB7-A5BD-E3DBEF5CC5F0

Q35212727-11EB5AC4-70BA-4B8C-AEE8-8406751B4D38

Q35212727-200D0830-A976-4AD8-9BE8-DCE307A0D7EF

Q35212727-22FCC8EC-2E6E-4937-98BF-D0A0C1E655B4

Q35212727-25D922C4-13D0-417A-A0E9-B4E370F4C9ED

Q35212727-2A4F0561-C248-4B2D-B46E-6D79F7A40C0A

Q35212727-2C93FAED-C0C5-4DA7-BB25-F6ED1ED34772

Q35212727-2CD5B3C7-F85A-4348-923C-5D7B5F669474

Q35212727-3BDF7D4F-A3B4-4CD6-B07C-757FA7938A8F

Q35212727-3BED3F77-0679-4120-9368-40217CC2EDF2

P304

Q35212727-3B8767DB-664F-4DF1-A544-3A3820A7BEBB

P31

Q35212727-C63F178D-20AA-4134-89D6-23350270E204

P356

Q35212727-AF3815E8-5835-498C-BECC-842DA32FF917

P407

Q35212727-3A8B35EE-DCE8-477E-A58A-48A10058A335

P433

Q35212727-77102BEE-788A-42D8-888E-43A943E9D6FD

P478

Q35212727-FC255AE3-242E-437C-9651-05E591ED2642

P50

Q35212727-01BD472A-15DA-44EB-9FCA-ECC36CCC9DDE

Q35212727-49CD0FB4-B0A8-42A1-94B0-39AF148C9EFB

P577

Q35212727-D346E195-4BDA-4262-9263-6F7DEBC70CDF

P5875

Q35212727-C5754442-16E5-4AB3-BC53-A4848A951A86

P698

Q35212727-31F7B838-856C-4375-96D9-F76146DE44B9

P932

Q35212727-F7F85D80-DA5A-4FFE-A6BF-462D54CCEC6A

P356

PNAS.1411848112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Assessment of ABT-263 activity ...... apy for small-cell lung cancer

@en

P2093

Ah Ting Tam

http://www.w3.org/2001/XMLSchema#string

Alan T Yeo

http://www.w3.org/2001/XMLSchema#string

Anahita Dastur

http://www.w3.org/2001/XMLSchema#string

Anna F Farago

http://www.w3.org/2001/XMLSchema#string

Anthony C Faber

http://www.w3.org/2001/XMLSchema#string

Bethany L Wagner

http://www.w3.org/2001/XMLSchema#string

Brad E Windle

http://www.w3.org/2001/XMLSchema#string

Carlotta Costa

http://www.w3.org/2001/XMLSchema#string

Charles T Jakubik

http://www.w3.org/2001/XMLSchema#string

Cyril H Benes

http://www.w3.org/2001/XMLSchema#string

P2860

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Systematic identification of genomic markers of drug sensitivity in cancer cells

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

Programmed anuclear cell death delimits platelet life span.

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

P304

E1288-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1411848112

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273787325

http://www.w3.org/2001/XMLSchema#string

P698

25737542

http://www.w3.org/2001/XMLSchema#string

P932

4371986

http://www.w3.org/2001/XMLSchema#string